Genetic testing of candidate genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia

European Journal of Medical Genetics

Volumn 55, Issue 4, 2012, Pages 225-234

  Campuzano, O ^a   Alcalde, M ^a   Berne, P ^b   Castro, V ^c   Guzzo, G ^c   Iglesias, A ^a   Alonso Pulpon, L ^c   Garcia Pavia, P ^c   Brugada, J ^b   Brugada, R ^a  

^a UNIVERSITY OF GIRONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Arrhythmogenic right ventricular cardiomyopathy dysplasia; Genetic testing; Sudden cardiac death

Indexed keywords

ACTIN ALPHA CARDIAC MUSCLE 1; CADHERIN 2 TYPE 1; CATENIN ALPHA 1; CONNEXIN 47; METAVINCULIN; MYOSIN LIGHT CHAIN 2; MYOSIN LIGHT CHAIN 3; NERVE CELL ADHESION MOLECULE; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GENETIC SCREENING; GENETIC VARIABILITY; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; MALE; PATHOGENESIS; SCHOOL CHILD; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPANISH INFLUENZA;

ADULT; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; BASE SEQUENCE; BIOLOGICAL MARKERS; CHILD; COHORT STUDIES; CYTOSKELETAL PROTEINS; FEMALE; GENETIC TESTING; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PEDIGREE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 84860352874     PISSN: 17697212     EISSN: 18780849     Source Type: Journal    
DOI: 10.1016/j.ejmg.2012.02.007     Document Type: Article

References (55)

1. Sen-Chowdhry S., Syrris P., Prasad S.K., et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J. Am. Coll. Cardiol. 2008, 52:2175-2187.
2. Azaouagh A., Churzidse S., Konorza T., Erbel R. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update. Clin. Res. Cardiol. 2011.
3. Sen-Chowdhry S., Morgan R.D., Chambers J.C., McKenna W.J. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annu. Rev. Med. 2010, 61:233-253.
4. van der Zwaag P.A., Jongbloed J.D., van den Berg M.P., et al. A genetic variants database for arrhythmogenic right ventricular dysplasia/cardiomyopathy. Hum. Mutat. 2009, 30:1278-1283.
5. McKenna W.J., Thiene G., Nava A., et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task force of the working group myocardial and pericardial disease of the European Society of Cardiology and of the scientific council on cardiomyopathies of the International Society and Federation of Cardiology. Br. Heart J. 1994, 71:215-218.
6. Marcus F.I., McKenna W.J., Sherrill D., et al. Diagnosis of arrhythmogenic right ventricular Cardiomyopathy/Dysplasia. Proposed modification of the task force criteria. Circulation 2010.
7. Andrews T.D., Cook S.S., Baumeister M., Hickey K.T. ARVC: help prevent sudden death. Nurse Pract. 2010, 35:26-33.
8. Taylor M., Graw S., Sinagra G., et al. Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. Circulation 2011.
9. Merner N.D., Hodgkinson K.A., Haywood A.F., et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am. J. Hum. Genet. 2008, 82:809-821.
10. Valenzise M., Arrigo T., De Luca F., et al. R298Q mutation of p63 gene in autosomal dominant ectodermal dysplasia associated with arrhythmogenic right ventricular cardiomyopathy. Eur. J. Med. Genet. 2008, 51:497-500.
11. Beffagna G., Occhi G., Nava A., et al. Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc. Res. 2005, 65:366-373.
12. Tiso N., Stephan D.A., Nava A., et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum. Mol. Genet. 2001, 10:189-194.
13. Sen-Chowdhry S., Syrris P., McKenna W.J. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J. Am. Coll. Cardiol. 2007, 50:1813-1821.
14. Sheikh F., Ross R.S., Chen J. Cell-cell connection to cardiac disease. Trends Cardiovasc. Med. 2009, 19:182-190.
15. Jamora C., Fuchs E. Intercellular adhesion, signalling and the cytoskeleton. Nat. Cell Biol. 2002, 4:E101-E108.
16. Meyer R.A., Laird D.W., Revel J.P., Johnson R.G. Inhibition of gap junction and adherens junction assembly by connexin and A-CAM antibodies. J. Cell Biol. 1992, 119:179-189.
17. Kostetskii I., Li J., Xiong Y., et al. Induced deletion of the N-cadherin gene in the heart leads to dissolution of the intercalated disc structure. Circ. Res. 2005, 96:346-354.
18. Li J., Patel V.V., Kostetskii I., et al. Cardiac-specific loss of N-cadherin leads to alteration in connexins with conduction slowing and arrhythmogenesis. Circ. Res. 2005, 97:474-481.
19. Aberle H., Schwartz H., Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J. Cell Biochem. 1996, 61:514-523.
20. Belkin A.M., Ornatsky O.I., Kabakov A.E., et al. Diversity of vinculin/meta-vinculin in human tissues and cultivated cells. Expression of muscle specific variants of vinculin in human aorta smooth muscle cells. J. Biol. Chem. 1988, 263:6631-6635.
21. Olson T.M., Illenberger S., Kishimoto N.Y., et al. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation 2002, 105:431-437.
22. Sohl G., Willecke K. Gap junctions and the connexin protein family. Cardiovasc. Res. 2004, 62:228-232.
23. Peters N.S., Green C.R., Poole-Wilson P.A., Severs N.J. Reduced content of connexin43 gap junctions in ventricular myocardium from hypertrophied and ischemic human hearts. Circulation 1993, 88:864-875.
24. Dupont E., Matsushita T., Kaba R.A., et al. Altered connexin expression in human congestive heart failure. J. Mol. Cell Cardiol. 2001, 33:359-371.
25. Smith J.H., Green C.R., Peters N.S., et al. Altered patterns of gap junction distribution in ischemic heart disease. An immunohistochemical study of human myocardium using laser scanning confocal microscopy. Am. J. Pathol. 1991, 139:801-821.
26. Elliott P., O'Mahony C., Syrris P., et al. Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopathy. Circ. Cardiovasc. Genet. 2010, 3:314-322.
27. Taylor M.R., Slavov D., Ku L., et al. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 2007, 115:1244-1251.
28. Monserrat L., Hermida-Prieto M., Fernandez X., et al. Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non-compaction, and septal defects. Eur. Heart J. 2007, 28:1953-1961.
29. Hermida-Prieto M., Monserrat L., Castro-Beiras A., et al. Familial dilated cardiomyopathy and isolated left ventricular noncompaction associated with lamin A/C gene mutations. Am. J. Cardiol. 2004, 94:50-54.
30. Vatta M., Mohapatra B., Jimenez S., et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J. Am. Coll. Cardiol. 2003, 42:2014-2027.
31. Elliott P., Andersson B., Arbustini E., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur. Heart J. 2008, 29:270-276.
32. Garcia-Pavia P., Syrris P., Salas C., et al. Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study. Heart 2011.
33. Solaro R.J. Sarcomere control mechanisms and the dynamics of the cardiac cycle. J. Biomed. Biotechnol. 2010, 2010:105648.
34. Olson T.M., Michels V.V., Thibodeau S.N., et al. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 1998, 280:750-752.
35. Mogensen J., Klausen I.C., Pedersen A.K., et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J. Clin. Invest. 1999, 103:R39-R43.
36. Matsson H., Eason J., Bookwalter C.S., et al. Alpha-cardiac actin mutations produce atrial septal defects. Hum. Mol. Genet. 2008, 17:256-265.
37. Takeichi M. Morphogenetic roles of classic cadherins. Curr. Opin. Cell Biol. 1995, 7:619-627.
38. Reid R.A., Hemperly J.J. Human N-cadherin: nucleotide and deduced amino acid sequence. Nucleic Acids Res. 1990, 18:5896.
39. Li J., Levin M.D., Xiong Y., et al. N-cadherin haploinsufficiency affects cardiac gap junctions and arrhythmic susceptibility. J. Mol. Cell Cardiol. 2008, 44:597-606.
40. Furukawa Y., Nakatsuru S., Nagafuchi A., et al. Structure, expression and chromosome assignment of the human catenin (cadherin-associated protein) alpha 1 gene (CTNNA1). Cytogenet. Cell Genet. 1994, 65:74-78.
41. Rudiger M. Vinculin and alpha-catenin: shared and unique functions in adherens junctions. Bioessays 1998, 20:733-740.
42. Toyofuku T., Yabuki M., Otsu K., et al. Intercellular calcium signaling via gap junction in connexin-43-transfected cells. J. Biol. Chem. 1998, 273:1519-1528.
43. Paznekas W.A., Boyadjiev S.A., Shapiro R.E., et al. Connexin 43 (GJA1) mutations cause the pleiotropic phenotype of oculodentodigital dysplasia. Am. J. Hum. Genet. 2003, 72:408-418.
44. Richardson R., Donnai D., Meire F., Dixon M.J. Expression of Gja1 correlates with the phenotype observed in oculodentodigital syndrome/type III syndactyly. J. Med. Genet. 2004, 41:60-67.
45. Pizzuti A., Flex E., Mingarelli R., et al. A homozygous GJA1 gene mutation causes a Hallermann-Streiff/ODDD spectrum phenotype. Hum. Mutat. 2004, 23:286.
46. Dasgupta C., Martinez A.M., Zuppan C.W., et al. Identification of connexin43 (alpha1) gap junction gene mutations in patients with hypoplastic left heart syndrome by denaturing gradient gel electrophoresis (DGGE). Mutat. Res. 2001, 479:173-186.
47. Poelzing S., Rosenbaum D.S. Altered connexin43 expression produces arrhythmia substrate in heart failure. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H1762-H1770.
48. Moiseyeva E.P., Weller P.A., Zhidkova N.I., et al. Organization of the human gene encoding the cytoskeletal protein vinculin and the sequence of the vinculin promoter. J. Biol. Chem. 1993, 268:4318-4325.
49. Belkin A.M., Ornatsky O.I., Glukhova M.A., Koteliansky V.E. Immunolocalization of meta-vinculin in human smooth and cardiac muscles. J. Cell Biol. 1988, 107:545-553.
50. Vasile V.C., Will M.L., Ommen S.R., et al. Identification of a metavinculin missense mutation, R975W, associated with both hypertrophic and dilated cardiomyopathy. Mol. Genet. Metab. 2006, 87:169-174.
51. Wadgaonkar R., Shafiq S., Rajmanickam C., Siddiqui M.A. Interaction of a conserved peptide domain in recombinant human ventricular myosin light chain-2 with myosin heavy chain. Cell Mol. Biol. Res. 1993, 39:13-26.
52. Poetter K., Jiang H., Hassanzadeh S., et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat. Genet. 1996, 13:63-69.
53. Li Y., Wu G., Tang Q., et al. Slow cardiac myosin regulatory light chain 2 (MYL2) was down-expressed in chronic heart failure patients. Clin. Cardiol. 2010, 34:30-34.
54. Fodor W.L., Darras B., Seharaseyon J., et al. Human ventricular/slow twitch myosin alkali light chain gene characterization, sequence, and chromosomal location. J. Biol. Chem. 1989, 264:2143-2149.
55. Christensen A.H., Benn M., Tybjaerg-Hansen A., et al. Screening of three novel candidate genes in arrhythmogenic right ventricular cardiomyopathy. Genet. Test. Mol. Biomarkers 2011.